Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

TLR2 mediates recognition of live staphylococus epidermidis

Staphylococcus epidermidis is a nosocomial pathogen that causes catheter-associated bacteremia in the immunocompromised, including those at the extremes of age

Research

Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections

This review aims to systematically identify and summarise the effects of different antifungal therapies in children with proven, probable or suspected...

Research

Diverging trends for lower respiratory infections in non-Aboriginal and Aboriginal children

To investigate temporal trends in admission rates for acute lower respiratory infections (ALRI) in a total population birth cohort of non-Aboriginal and...

Research

Vaccinating young adults against HPV: the importance of understanding health decision-making and behaviour

Vaccination of young teenage females against human papillomavirus (HPV) with a newly licenced quadrivalent vaccine designed to prevent cervical cancer and...

News & Events

New meningococcal strains bring increased risk in WA

A new study has confirmed the changing pattern of meningococcal disease in Western Australia.

Research

A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults

No currently licensed and available vaccine has been shown to provide broad protection against endemic MnB disease.

Research

Cohort profile: A population-based record linkage platform to address critical epidemiological evidence gaps in respiratory syncytial virus and other respiratory infections

The Western Australia (WA) Respiratory Infections Linked Data Platform is a population-based cohort established to investigate the epidemiology of RSV and other respiratory infections in children aged 0-10 years, incorporating microbiological testing patterns, hospital admissions, emergency department presentations, and socio-demographic data.

Research

Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape

Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years). Efforts to develop a respiratory syncytial virus vaccine or immunoprophylaxis remain highly active.